IN2014DN06213A - - Google Patents
Info
- Publication number
- IN2014DN06213A IN2014DN06213A IN6213DEN2014A IN2014DN06213A IN 2014DN06213 A IN2014DN06213 A IN 2014DN06213A IN 6213DEN2014 A IN6213DEN2014 A IN 6213DEN2014A IN 2014DN06213 A IN2014DN06213 A IN 2014DN06213A
- Authority
- IN
- India
- Prior art keywords
- linezolid
- isomer
- relative
- hydroxide
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to a substantially pure linezolid hydroxide having R isomer content more than about 99.9% relative to its S isomer. Further aspect of invention provides the ambient moisture condition which is critical for enantiomeric pure linezolid hydroxide. The obtained substantially enantiomerically pure linezolid hydroxide compound of formula II can be subsequently converted into the linezolid compound of formula I having S isomer content more than 99.9% relative to R isomer. Further the invention provides an improved process for preparation of enantiomeric pure linezolid Form I wherein linezolid Form I having the purity more than 99.9% relative to any other known polymorphic form of linezolid. The obtained enantiomeric pure linezolid Form I can be subsequently converted into the other known polymorphic forms linezolid. The invention also provides stable and substantially solvent free crystal of Form I of linezolid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6213DEN2014 IN2014DN06213A (en) | 2012-01-24 | 2013-01-22 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2254DE2012 | 2012-07-19 | ||
IN267DE2012 IN2012DE00267A (en) | 2012-01-31 | 2013-01-22 | |
PCT/IB2013/050537 WO2013111048A1 (en) | 2012-01-24 | 2013-01-22 | Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent |
IN200DE2012 IN2012DE00200A (en) | 2012-01-24 | 2013-01-22 | |
IN6213DEN2014 IN2014DN06213A (en) | 2012-01-24 | 2013-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06213A true IN2014DN06213A (en) | 2015-10-23 |
Family
ID=47884428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6213DEN2014 IN2014DN06213A (en) | 2012-01-24 | 2013-01-22 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20150025236A1 (en) |
EP (1) | EP2852580A1 (en) |
IN (1) | IN2014DN06213A (en) |
WO (1) | WO2013111048A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108117527A (en) * | 2018-01-12 | 2018-06-05 | 上海龙翔生物医药开发有限公司 | A kind of I preparation method of linezolid form suitable for industrialized production |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
MY115155A (en) * | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
CZ200788A3 (en) | 1996-04-11 | 2017-01-25 | Pfizer Inc. | A method of preparation of 5-aminomethyl substituted oxazolidinone amines |
JP2001522828A (en) | 1997-11-07 | 2001-11-20 | ファルマシア・アンド・アップジョン・カンパニー | Oxazolidinone production |
AR027261A1 (en) | 2000-02-02 | 2003-03-19 | Upjohn Co | LINEZOLID CRYSTAL FORM II |
US6444813B2 (en) * | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
DK1673370T3 (en) | 2003-10-16 | 2009-12-07 | Symed Labs Ltd | Crystalline form of linezolid |
US7291614B2 (en) | 2005-02-24 | 2007-11-06 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
WO2009032294A2 (en) | 2007-09-06 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of a linezolid intermediate, linezolid hydroxide |
WO2009063505A2 (en) * | 2007-10-08 | 2009-05-22 | Usv Limited | Process for preparation of (s) (n-[[3-[3-fluoro-4-(4-morpholinyl) hen l -2-oxo-5-oxazolidin l methyl]acetamide |
WO2010084514A2 (en) | 2009-01-02 | 2010-07-29 | Neuland Laboratories Ltd. | A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide |
WO2011050826A1 (en) * | 2009-10-28 | 2011-05-05 | Synthon B.V. | Process for making crystalline form a of linezolid |
CA2785620A1 (en) | 2009-12-26 | 2011-06-30 | Alembic Pharmaceuticals Limited | Process for the preparation of linezolid |
WO2011114210A2 (en) | 2010-03-15 | 2011-09-22 | Jubilant Life Sciences Limited | Processes for the preparation of linezolid |
WO2014013498A1 (en) * | 2012-07-17 | 2014-01-23 | Symed Labs Limited | Amorphous coprecipitates of linezolid |
-
2013
- 2013-01-22 IN IN6213DEN2014 patent/IN2014DN06213A/en unknown
- 2013-01-22 US US14/374,213 patent/US20150025236A1/en not_active Abandoned
- 2013-01-22 EP EP13709542.8A patent/EP2852580A1/en not_active Withdrawn
- 2013-01-22 WO PCT/IB2013/050537 patent/WO2013111048A1/en active Application Filing
-
2016
- 2016-11-18 US US15/356,374 patent/US20170066728A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170066728A1 (en) | 2017-03-09 |
EP2852580A1 (en) | 2015-04-01 |
WO2013111048A1 (en) | 2013-08-01 |
US20150025236A1 (en) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013006926A (en) | Photochromic compounds and compositions. | |
NZ739757A (en) | Processes for preparing jak inhibitors and related intermediate compounds | |
NZ600119A (en) | Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives | |
NZ626505A (en) | Substituted pyrrolidine-2-carboxamides | |
UA110354C2 (en) | Anti-viral compounds | |
IN2014MN01521A (en) | ||
MX350211B (en) | Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy )-acetimidic acid ethyl ester. | |
MX340125B (en) | Storage-stable 2-hydroxy-4-(methylthio) butyric acid nitrile. | |
EP2590649A4 (en) | Process for the synthesis of substituted morphinans | |
IN2014DN10617A (en) | ||
BR112014004523A2 (en) | flavoring compound and composition | |
IN2014DN00144A (en) | ||
IN2014MN00976A (en) | ||
IN2013MU03442A (en) | ||
WO2013190455A3 (en) | Process for the preparation of lurasidone hydrochloride | |
MX342273B (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-yl methyl-indol-1-yl)-acetic acid esters. | |
WO2014087208A3 (en) | A process of preparing alcaftadine | |
BR112015015880A2 (en) | A process for producing the compound, compound of formula, pharmaceutical preparation and substantially innovative compounds, compositions, methods and uses | |
IN2014DN06213A (en) | ||
WO2018125983A8 (en) | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors | |
EP4282973A3 (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
MX2013004193A (en) | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives. | |
NZ711329A (en) | A process for preparation of (2s, 5r)- sulfuric acid mono-{ [(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester | |
EA201201293A1 (en) | HYDRATE OF HYDROBROMIDE AGOMELATIN AND ITS GETTING | |
NZ606574A (en) | Novel synthesis for thiazolidinedione compounds |